The role of beta-blockers in septic patients

Minerva Anestesiologica

Volumn 81, Issue 3, 2015, Pages 312-319

  Hamzaoui, O ^a   Teboul, J L ^b,c  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Catecholamines; Esmolol; Propranolol; Septic; Shock; Tachycardia

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESMOLOL;

ADRENERGIC STIMULATION; ARTICLE; CARDIOSELECTIVITY; CARDIOVASCULAR EFFECT; CATABOLISM; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; GLUCOSE METABOLISM; HEART LEFT VENTRICLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART PERFORMANCE; HEART RATE; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERMETABOLISM; IMMUNOMODULATION; LUNG HEMODYNAMICS; NEUROMUSCULAR SYNAPSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; SKELETAL MUSCLE; SYSTEMIC VASCULAR RESISTANCE; DRUG EFFECTS; PATHOPHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; HEMODYNAMICS; HUMANS; SEPSIS;

EID: 84930010713     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988;260:2088-93.
2. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
3. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91.
4. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
5. Fleischmann KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK et al. 2009 ACCF/AHA focused update on perioperative beta blockade: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009;120:2123-51.
6. Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of secure randomised controlled trials of β-blockade perioperative death in non-cardiac-surgery. Heart 2014;100:456-64.
7. Haffner CA, Kendall MJ. Metabolic effects of beta 2-agonists. J Clin Pharm Ther 1992;17:155-64.
8. Lang C. Sepsis-induced insulin resistance in rats is mediated by a beta-adrenergic mechanism. Am J Physiol Endocrinol Metab 1992;263:E703-11.
9. Hargrove DM, Bagby GJ, Lang CH, Spitzer JJ. Adrenergic blockade prevents endotoxin induced increases in glucose metabolism. Am J Physiol 1988;255:E629-35.
10. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001;345:1223-9.
11. Barrow RE, Wolfe RR, Dasu MR, Barrow LN, Herndon DN. The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly. Ann Surg 2006;243:115-20.
12. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006;139:686-94.
13. Khan MM, Sansoni P, Silverman ED, Engleman EG, Melmon KL. Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. Biochem Pharmacol 1986;35:1137-42.
14. Landmann RM, Burgisser E, Wesp M, Bühler FR. Beta-adrenergic receptors are different in subpopulations of human circulating lymphocytes. J Recept Res 1984;4:37-50.
15. Oberbeck R. Catecholamines: Physiological immunomodulators during health and illness. Curr Med Chem 2006;13:1979-89.
16. Takahashi H, Kobayashi M, Tsuda Y, Herndon DN, Suzuki F. Contribution of the sympathetic nervous system on the burn-associated impairment of CCL3 production. Cytokine 2005;29:208-14.
17. Christensen S, Johansen MB, Tønnesen E, Larsson A, Pedersen L, Lemeshow S et al. Preadmission beta-blocker use and 30-day mortality among patients in intensive care: a cohort study. Crit Care 2011;15:R87.
18. Bernardin G, Strosberg AD, Bernard A, Mattei M, Marullo S. β-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med 1998;24:1315-22.
19. Annane D, Trabold F, Sharshar T, Jarrin I, Blanc AS, Raphael JC et al. Inappropriate sympathetic activation at onset of septic shock: A spectral analysis approach. Am J Respir Crit Care Med 1999;160:458-65.
20. Brodde OE. The functional importance of beta1 and beta2 adrenoreceptors in the human heart. Am J Cardiol 1988;62:24C-9C.
21. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
22. Silverman HJ, Penaranda R, Orens JB, Lee NH. Impaired beta-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993;21:31-9.
23. Abi-Gerges N, Tavernier B, Mebazaa A, Faivre V, Paqueron X, Payen D, et al. Sequential changes in autonomic regulation of cardiac, myocytes after in vivo endotoxin injection in rat. Am J Respir Crit Care Med 1999;160:1196-204.
24. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990;67:753-63.
25. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA 1989;86: 6753-7.
26. Cariou A, Pinsky MR, Monchi M, Laurent I, Vinsonneau C, Chiche JD et al. Is myocardial adrenergic responsiveness depressed in human septic shock? Intensive Care Med 2008; 34:917-22.
27. Jozwiak M, Persichini R, Monnet X, Teboul JL. Management of myocardial dysfunction in severe sepsis. Semin Respir Crit Care Med 2011;32:206-14.
28. Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005;33:2294-301.
29. Ackland GL, Yao ST, Poputnikov D, Dyson A, Stidwill R, Poputnikov D et al. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1 adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2010;38:388-94.
30. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor-α and interleukin 1β are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183:949-58.
31. Cain BS, Meldrum DR, Dinarello CA, Meng X, Joo KS, Banerjee A et al. Tumor necrosis factor-alpha and interleukin-1 beta synergistically depress human myocardial function. Crit Care Med 1999;27:1309-18.
32. Berk JL, Hagen JF, Beyer WH, Gerber MJ, Dochat GR. The treatment of endotoxin shock by beta adrenergic blockade. Ann Surg 1969;169:74-81.
33. Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs 2012;72:109-32
34. Benfield P, Sorkin EM. Esmolol. a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1987;33:392-412.
35. Aboab J, Sebille V, Jourdain M, Mangalaboyi J, Gharbi M, Mansart A et al. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med 2011;37:1344-51.
36. Gore DC, Honeycutt D, Jahoor F, Barrow RE, Wolfe RR, Herndon DN. Propranolol diminishes extremity blood flow in burned patients. Ann Surg 1991;213:568-73.
37. Berk JL, Hagen JF, Maly G, Koo R. The treatment of shock with beta adrenergic blockade. Arch Surg 1972;104:46-51.
38. Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013;310:1683-91.
39. Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A et al. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 2013;41:2162-8.
40. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014;311:1308-16.
41. ProCESS Investigators, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014;370:1683-93.
42. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2014;42:625-31.
43. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.